Glucosamine/L-lactide copolymers as potential carriers for the development of a sustained rifampicin release system using Mycobacterium smegmatis as a tuberculosis model

The present study aims at developing a new, ultrafine particle-based efficient antibiotic delivery system for the treatment of tuberculosis. The carrier material to make the rifampicin (RIF)-loaded particles is a low molecular weight star-shaped polymer produced from glucosamine (core building unit)...

Full description

Bibliographic Details
Main Authors: Jorge Ragusa, Daniela Gonzalez, Sumin Li, Sandra Noriega, Maciej Skotak, Gustavo Larsen
Format: Article
Language:English
Published: Elsevier 2019-04-01
Series:Heliyon
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2405844019305080
id doaj-6ac9b77a853d43abae0d7adc3cf841ef
record_format Article
spelling doaj-6ac9b77a853d43abae0d7adc3cf841ef2020-11-25T02:09:51ZengElsevierHeliyon2405-84402019-04-0154e01539Glucosamine/L-lactide copolymers as potential carriers for the development of a sustained rifampicin release system using Mycobacterium smegmatis as a tuberculosis modelJorge Ragusa0Daniela Gonzalez1Sumin Li2Sandra Noriega3Maciej Skotak4Gustavo Larsen5LNK Chemsolutions LLC, 4701 Innovation Drive, Lincoln, NE, 68521, USA; Department of Chemical and Biomolecular Engineering, University of Nebraska, Lincoln, NE, 68588-0643, USALNK Chemsolutions LLC, 4701 Innovation Drive, Lincoln, NE, 68521, USA; Department of Chemical and Biomolecular Engineering, University of Nebraska, Lincoln, NE, 68588-0643, USALNK Chemsolutions LLC, 4701 Innovation Drive, Lincoln, NE, 68521, USALNK Chemsolutions LLC, 4701 Innovation Drive, Lincoln, NE, 68521, USADepartment of Chemical and Biomolecular Engineering, University of Nebraska, Lincoln, NE, 68588-0643, USALNK Chemsolutions LLC, 4701 Innovation Drive, Lincoln, NE, 68521, USA; Department of Chemical and Biomolecular Engineering, University of Nebraska, Lincoln, NE, 68588-0643, USA; Corresponding author.The present study aims at developing a new, ultrafine particle-based efficient antibiotic delivery system for the treatment of tuberculosis. The carrier material to make the rifampicin (RIF)-loaded particles is a low molecular weight star-shaped polymer produced from glucosamine (core building unit) and L-lactide (GluN-LLA). Particles were made via electrohydrodynamic atomization. Prolonged release (for up to 14 days) of RIF from these particles is reported. Drug release data fits the Korsmeyer-Peppas equation, which suggests the occurrence of a modified diffusion-controlled RIF release mechanism in vitro and is also supported by differential scanning calorimetry and drug leaching tests. Cytotoxicity tests on Mycobacterium smegmatis showed that antibiotic-free GluN-LLA and polylactides (PLA) particles (reference materials) did not show any significant anti-bacterial activity. The minimum inhibitory concentration and minimum bactericidal concentration values obtained for RIF-loaded particles showed 2- to 4-fold improvements in the anti-bacterial activity relative to the free drug. Cytotoxicity tests on macrophages indicated that cell death correlates with an increase of particle concentration but is not significantly affected by material type or particle size. Confocal microscopy was used to track internalization and localization of particles in the macrophages. The uptake of GluN-LLA particles is higher than those of their PLA counterparts. In addition, after phagocytosis, the GluN-LLA particles stayed in the cytoplasm and showed favorable long-term drug release behavior, which facilitated the killing of intracellular bacteria when compared to free RIF. The present studies suggest that these drug carrier materials are potentially very attractive candidates for the development of high-payload, sustained-release antibiotic/resorbable polymer particle systems for treating bacterial lung infections.http://www.sciencedirect.com/science/article/pii/S2405844019305080MicrobiologyPharmaceutical chemistryPharmaceutical science
collection DOAJ
language English
format Article
sources DOAJ
author Jorge Ragusa
Daniela Gonzalez
Sumin Li
Sandra Noriega
Maciej Skotak
Gustavo Larsen
spellingShingle Jorge Ragusa
Daniela Gonzalez
Sumin Li
Sandra Noriega
Maciej Skotak
Gustavo Larsen
Glucosamine/L-lactide copolymers as potential carriers for the development of a sustained rifampicin release system using Mycobacterium smegmatis as a tuberculosis model
Heliyon
Microbiology
Pharmaceutical chemistry
Pharmaceutical science
author_facet Jorge Ragusa
Daniela Gonzalez
Sumin Li
Sandra Noriega
Maciej Skotak
Gustavo Larsen
author_sort Jorge Ragusa
title Glucosamine/L-lactide copolymers as potential carriers for the development of a sustained rifampicin release system using Mycobacterium smegmatis as a tuberculosis model
title_short Glucosamine/L-lactide copolymers as potential carriers for the development of a sustained rifampicin release system using Mycobacterium smegmatis as a tuberculosis model
title_full Glucosamine/L-lactide copolymers as potential carriers for the development of a sustained rifampicin release system using Mycobacterium smegmatis as a tuberculosis model
title_fullStr Glucosamine/L-lactide copolymers as potential carriers for the development of a sustained rifampicin release system using Mycobacterium smegmatis as a tuberculosis model
title_full_unstemmed Glucosamine/L-lactide copolymers as potential carriers for the development of a sustained rifampicin release system using Mycobacterium smegmatis as a tuberculosis model
title_sort glucosamine/l-lactide copolymers as potential carriers for the development of a sustained rifampicin release system using mycobacterium smegmatis as a tuberculosis model
publisher Elsevier
series Heliyon
issn 2405-8440
publishDate 2019-04-01
description The present study aims at developing a new, ultrafine particle-based efficient antibiotic delivery system for the treatment of tuberculosis. The carrier material to make the rifampicin (RIF)-loaded particles is a low molecular weight star-shaped polymer produced from glucosamine (core building unit) and L-lactide (GluN-LLA). Particles were made via electrohydrodynamic atomization. Prolonged release (for up to 14 days) of RIF from these particles is reported. Drug release data fits the Korsmeyer-Peppas equation, which suggests the occurrence of a modified diffusion-controlled RIF release mechanism in vitro and is also supported by differential scanning calorimetry and drug leaching tests. Cytotoxicity tests on Mycobacterium smegmatis showed that antibiotic-free GluN-LLA and polylactides (PLA) particles (reference materials) did not show any significant anti-bacterial activity. The minimum inhibitory concentration and minimum bactericidal concentration values obtained for RIF-loaded particles showed 2- to 4-fold improvements in the anti-bacterial activity relative to the free drug. Cytotoxicity tests on macrophages indicated that cell death correlates with an increase of particle concentration but is not significantly affected by material type or particle size. Confocal microscopy was used to track internalization and localization of particles in the macrophages. The uptake of GluN-LLA particles is higher than those of their PLA counterparts. In addition, after phagocytosis, the GluN-LLA particles stayed in the cytoplasm and showed favorable long-term drug release behavior, which facilitated the killing of intracellular bacteria when compared to free RIF. The present studies suggest that these drug carrier materials are potentially very attractive candidates for the development of high-payload, sustained-release antibiotic/resorbable polymer particle systems for treating bacterial lung infections.
topic Microbiology
Pharmaceutical chemistry
Pharmaceutical science
url http://www.sciencedirect.com/science/article/pii/S2405844019305080
work_keys_str_mv AT jorgeragusa glucosaminellactidecopolymersaspotentialcarriersforthedevelopmentofasustainedrifampicinreleasesystemusingmycobacteriumsmegmatisasatuberculosismodel
AT danielagonzalez glucosaminellactidecopolymersaspotentialcarriersforthedevelopmentofasustainedrifampicinreleasesystemusingmycobacteriumsmegmatisasatuberculosismodel
AT suminli glucosaminellactidecopolymersaspotentialcarriersforthedevelopmentofasustainedrifampicinreleasesystemusingmycobacteriumsmegmatisasatuberculosismodel
AT sandranoriega glucosaminellactidecopolymersaspotentialcarriersforthedevelopmentofasustainedrifampicinreleasesystemusingmycobacteriumsmegmatisasatuberculosismodel
AT maciejskotak glucosaminellactidecopolymersaspotentialcarriersforthedevelopmentofasustainedrifampicinreleasesystemusingmycobacteriumsmegmatisasatuberculosismodel
AT gustavolarsen glucosaminellactidecopolymersaspotentialcarriersforthedevelopmentofasustainedrifampicinreleasesystemusingmycobacteriumsmegmatisasatuberculosismodel
_version_ 1724922134771269632